Drug Profile
Omalizumab biosimilar - Mycenax Biotech
Latest Information Update: 24 Nov 2021
Price :
$50
*
At a glance
- Originator Mycenax Biotech
- Class Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action IgE receptor antagonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Allergic asthma; Chronic urticaria
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Allergic-asthma in Taiwan (Parenteral)
- 28 Sep 2021 No recent reports of development identified for preclinical development in Chronic-urticaria in Taiwan (Parenteral)
- 09 Aug 2017 Preclinical trials in Allergic asthma in Taiwan (Parenteral) before August 2017 (Mycenax Biotech pipeline, August 2017)